Inventor · disambiguated record
Pavel Strop
Also filed as: STROP PAVEL
29 granted patents·14 pending applications·341 citations·filing 2011–2024
97Inventor score
Top patents by PatentIndex Score
43 records- 0198US8871908B2Antibodies specific for Trop-2 and their usesRINAT NEUROSCIENCE CORP·Filed 2012·Granted Oct 28, 2014·86 cites·26 claims
- 0297US10138303B2Heterodimeric proteins and methods for producing and purifying themRINAT NEUROSCIENCE CORP·Filed 2016·Granted Nov 27, 2018·14 cites·9 claims
- 0396US11814435B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Nov 14, 2023·5 cites·7 claims
- 0496US9969809B2Therapeutic antibodies and their usesPFIZER·Filed 2016·Granted May 15, 2018·44 cites·8 claims
- 0596US9399074B2Antibodies specific for trop-2 and their usesRINAT NEUROSCIENCE CORP·Filed 2014·Granted Jul 26, 2016·19 cites·19 claims
- 0695US11155630B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Oct 26, 2021·3 cites·14 claims
- 0795US9527926B2Heterodimeric proteins and methods for producing and purifying themHO WEI-HSIEN·Filed 2011·Granted Dec 27, 2016·44 cites·10 claims
- 0894US9676871B2Engineered polypeptide conjugates and methods for making thereof using transglutaminaseSTROP PAVEL·Filed 2011·Granted Jun 13, 2017·40 cites·19 claims
- 0994US8828401B2Cytotoxic peptides and antibody drug conjugates thereofPFIZER·Filed 2012·Granted Sep 9, 2014·35 cites·36 claims
- 1091US10793635B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 1189US10040860B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Aug 7, 2018·6 cites·8 claims
- 1288US9249186B2Cytotoxic peptides and antibody drug conjugates thereofPFIZER·Filed 2015·Granted Feb 2, 2016·7 cites·5 claims
- 1386US9175093B2PCSK9 antagonistsRINAT NEUROSCIENCE CORP·Filed 2013·Granted Nov 3, 2015·6 cites·11 claims
- 1485US9138486B2Cytotoxic peptides and antibody drug conjugates thereofPFIZER·Filed 2014·Granted Sep 22, 2015·7 cites·29 claims
- 1585US2024018252A1Therapeutic antibodies and their usesPFIZER·Filed 2023·Application pending·0 cites
- 1684US10842881B2Engineered polypeptide conjugates using transglutaminaseRINAT NEUROSCIENCE CORP·Filed 2018·Granted Nov 24, 2020·2 cites·6 claims
- 1784US10689458B2Site specific HER2 antibody drug conjugatesPFIZER·Filed 2016·Granted Jun 23, 2020·3 cites·6 claims
- 1883US11242393B2Antibodies against MICA and/or MICB and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 8, 2022·3 cites·19 claims
- 1983US8715673B2Staphylococcus aureus specific antibodies and uses thereofRINAT NEUROSCIENCE CORP·Filed 2012·Granted May 6, 2014·4 cites·15 claims
- 2081US11602525B2Antibody-drug conjugates with high drug loadingRINAT NEUROSCIENCE CORP·Filed 2015·Granted Mar 14, 2023·2 cites·17 claims
- 2181US11390689B2Heterodimeric proteins and methods for producing and purifying themRINAT NEUROSCIENCE CORP·Filed 2018·Granted Jul 19, 2022·1 cites·12 claims
- 2280US12478674B2Ipilimumab variants with enhanced specificity for binding at low pHBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Nov 25, 2025·1 cites·10 claims
- 2378US2022332850A1Heterodimeric proteins and methods for producing and purifying themRINAT NEUROSCIENCE CORP·Filed 2022·Application pending·0 cites
- 2476US10195289B2Engineered polypeptide conjugates using transglutaminaseRINAT NEUROSCIENCE CORP·Filed 2014·Granted Feb 5, 2019·3 cites·17 claims
- 2576US10100114B2Antibodies specific for TROP-2 and their usesRINAT NEUROSCIENCE CORP·Filed 2016·Granted Oct 16, 2018·1 cites·9 claims
- 2676US2024009319A1Engineered polypeptide conjugates using transglutaminaseRINAT NEUROSCIENCE CORP·Filed 2023·Application pending·0 cites
- 2774US11993625B2Calicheamicin derivatives and antibody drug conjugates thereofPFIZER·Filed 2018·Granted May 28, 2024·1 cites·16 claims
- 2872US2024409573A1Calicheamicin derivatives and antibody drug conjugates thereofPFIZER·Filed 2024·Application pending·0 cites
- 2967US2021115159A1Engineered polypeptide conjugates and methods for making thereof using transglutaminasePFIZER·Filed 2020·Application pending·0 cites
- 3065US2021162058A1Engineered polypeptide conjugates using transglutaminaseRINAT NEUROSCIENCE CORP·Filed 2020·Application pending·0 cites
- 3164US11091544B2Antibodies specific for Trop-2 and their usesRINAT NEUROSCIENCE CORP·Filed 2018·Granted Aug 17, 2021·0 cites·8 claims
- 3264US2024382610A1Nectin-4 antibodies and conjugatesTALLAC THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3363US10941216B2Engineered polypeptide conjugates and methods for making thereof using transglutaminasePFIZER·Filed 2017·Granted Mar 9, 2021·0 cites·6 claims
- 3463US2022281980A1Antibodies against mica and/or micb and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3562US2021205463A1Stability-modulating linkers for use with antibody drug conjugatesPFIZER·Filed 2021·Application pending·0 cites
- 3657US2020377615A1Site specific her2 antibody drug conjugatesPFIZER·Filed 2020·Application pending·0 cites
- 3756US2023140384A1Antibodies to cd40 with enhanced agonist activityBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3854US10967068B2Stability-modulating linkers for use with antibody drug conjugatesPFIZER·Filed 2015·Granted Apr 6, 2021·0 cites·2 claims
- 3954US2016096898A1Pc33718eRINAT NEUROSCIENCE CORP·Filed 2015·Application pending·0 cites
- 4053US12290570B2Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and usesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted May 6, 2025·0 cites·23 claims
- 4152US2023416364A1Methods of redirecting of il-2 to target cells of interestBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 4249US2023119066A1Anti-ccr8 antibodies for treating cancerBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 4345US12478686B2Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and usesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 25, 2025·0 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when Pavel Strop files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →